Gefitinib Inhibits the Growth and Invasion of Urothelial Carcinoma Cell Lines in which Akt and MAPK Activation Is Dependent on Constitutive Epidermal Growth Factor Receptor Activation

Nicolle, GaëlleDaher, AhmedMaillé, PascaleVermey, MarcelLoric, SylvainBakkar, AshrafWallerand, HervéVordos, DimitriosVacherot, FrancisGil Diez De Medina, SixtinaC Abbou, ClaudeVan der Kwast, TheodoreThiery, Jean-PaulRadvanyi, FrançoisK Chopin, Dominique2020-02-112020-02-1120061078-0432https://doi.org/10.1158/1078-0432.CCR-05-2148https://cutt.ly/krHztO6MSA Google ScholarAbnormally high levels of epidermal growth factor receptor (EGFR) protein are associated with advanced tumor stage/grade. The objective of this study was to evaluate the effects of the specific EGFR tyrosine kinase inhibitor gefitinib on activation of the Akt and mitogen-activated protein kinase (MAPK) pathways in human urothelial cell carcinoma (UCC) cell lines and to identify potential markers of gefitinib responsiveness in biopsy samples of UCC.enUniversity for Gefitinib InhibitsCarcinomaCell LinesMAPK ActivationFactor ReceptorGefitinib Inhibits the Growth and Invasion of Urothelial Carcinoma Cell Lines in which Akt and MAPK Activation Is Dependent on Constitutive Epidermal Growth Factor Receptor ActivationArticlehttps://doi.org/10.1158/1078-0432.CCR-05-2148